Clinical trial · Interventional
Safety and Efficacy of Immune Therapy for Condyloma
NCT03158480CI-TRIAL-00028337unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cytokine-induced killer (CIK) cells will be co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to Condylomata Acuminata patients using interferon, whose recurrence rate and total cost will be compared to Condylomata Acuminata patients only use interferon.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Condylomata Acuminata | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DC-CIK immunotherapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- DC-CIK+interferon Group
- description
- dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy plus interferon intervention
- interventionNames
- Biological: DC-CIK immunotherapy
- type
- PLACEBO_COMPARATOR
- label
- Placebo+interferon Group
- description
- saline as placebo plus interferon intervention
- interventionNames
- Biological: DC-CIK immunotherapy
Primary outcomes (1)
- measure
- Condylomata Acuminata recurrence rate
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria:All patients have typical clinical characters of condyloma, positive for HPV-DNA test; All patients have been treated for cryotherapy or laser plus interferon for over half a year without completely recovery. All patients or their family will sign informed consent and approved by Ethics Committee of Shenzhen Second People's Hospital - Exclusion Criteria:pregnant, blood disease, contraindication for immune therapy, allergic to interferon \-
References
Publications (0)
Data not yet available
No reference posted for this study.